From: Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib
IC50
Hcc827
PC-9
PC-9/GR
H1650
Paclitaxel
2.27 ± 0.15nM
2.33 ± 0.47nM
2.59 ± 0.62nM
3.29 ± 0.35nM
Gefitinib
16 ± 1.12nM
19 ± 2nM
2.1 ± 0.39 μM
9.37 ± 0.52 μM